ArticleBMC infectious diseases2017
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Visceral leishmaniasis in leukemia patients, a great neglected disease in endemic countries: report of a retrospective study and systematic literature review.BMC infectious diseases · 2026Pooled it
- A comprehensive systematic review of leishmaniasis in patients undergoing drug-induced immunosuppression for the treatment of dermatological, rheumatological and gastroenterological diseases.Revista do Instituto de Medicina Tropical de Sao Paulo · 2020Pooled it
- Article
- Ex vivo effects of oclacitinib and cyclosporin A on canine immune response to Leishmania infantum.Scientific reports · 2026Article
- Insights into drug resistance inADMET & DMPK · 2026Review
- Cutaneous Leishmaniasis in the Immunocompromised: Diagnostic and Therapeutic Insights from a Case Documented in Central Italy.Infectious disease reports · 2025Article
- Case Report: Disseminated leishmaniasis and rheumatoid arthritis: navigating a clinical conundrum.Frontiers in immunology · 2025Article
- Systematic Review of Treatment Failure and Clinical Relapses in Leishmaniasis from a Multifactorial Perspective: Clinical Aspects, Factors Associated with the Parasite and Host.Tropical medicine and infectious disease · 2023Review
- Article
- Evaluation of the In Vitro Antiparasitic Effect of the Essential Oil ofMolecules (Basel, Switzerland) · 2022Article
- Causative Agents of American Tegumentary Leishmaniasis Are Able to Infect 3T3-L1 AdipocytesFrontiers in cellular and infection microbiology · 2022Article
- Article
- Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid-induced immunosuppression.Clinical case reports · 2021Article
- Visceral Dissemination of Mucocutaneous Leishmaniasis in a Kidney Transplant Recipient.Pathogens (Basel, Switzerland) · 2020Article
- Immune Profile of the Nasal Mucosa in Patients with Cutaneous Leishmaniasis.Infection and immunity · 2020Article
- Secondary Prophylaxis with Liposomal Amphotericin B in a Patient with Mucosal Leishmaniasis Undergoing Immunobiological Therapy for Active Ankylosing Spondylitis.The American journal of tropical medicine and hygiene · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or malignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis, which rarely occur together or consecutively. CASE PRESENTATION: The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe rheumatoid arthritis. She underwent bone marrow biopsy to explore thrombocytopenia. Diagnosis of visceral leishmaniasis was made by identification of Leishman Donovan (LD) bodies in macrophages. Treatment with liposomal amphotericin B was successful. She later developed cutaneous leishmaniasis treated with amphotericin B lipid complex. She next presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies. Biopsy confirmed the diagnosis of leishmaniasis. Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated. She later presented a recurrent bone marrow involvement treated with intramuscular paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a mucosal destruction of the nose. A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as etiological agent.
conclusionsClinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic localizations of Leishmania in immunosuppressed patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.